Answers are grounded in this paper and cite their sources.
Examines the impact of LIF and OSM on acute endometritis, suggesting new therapeutic pathways.
Summary Acute endometritis, often triggered by Gram-negative bacterial endotoxins such as lipopolysaccharide (LPS), disrupts endometrial integrity, induces robust pro-inflammatory macrophage activation, and compromises uterine function, potentially leading to infertility and adverse pregnancy outcomes. Here, we demonstrate that IL-6 family cytokines, Leukemia Inhibitory Factor (LIF) and Oncostatin M (OSM), exert complementary yet distinct immunoregulatory effects that mitigate LPS-induced acute endometritis in vivo. Both cytokines preserved endometrial architecture, limited neutrophil and macrophage infiltration, suppressed cytotoxic iNOS expression, and promoted macrophage-mediated tissue repair, with OSM providing superior systemic and hepatoprotective effects. Mechanistically, these outcomes were linked to STAT3-dependent Mφ reprogramming toward anti-inflammatory M2 phenotypes, with OSM additionally engaging SMAD2 pathways to favor CD163 M2 macrophages marker, whereas LIF preferentially induced anti-inflammatory M2 subsets engaging STAT3 alone. Our findings highlight the therapeutic potential of LIF and OSM as modulators of uterine immune homeostasis and macrophage plasticity modulating and mitigating LPS-acute endometritis and preserving endometrial integrity.
No takes yet. Share an insight, caveat, or question.
Ravelojaona et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: